+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Therapeutics for Women's Health: Technologies and Global Markets- Product Image
Therapeutics for Women's Health: Technologies and Global Markets- Product Image
New

Therapeutics for Women's Health: Technologies and Global Markets

  • PDF Icon

    Report

  • 159 Pages
  • March 2025
  • Region: Global
  • BCC Research
  • ID: 3743712
Description Jump to:
The global therapeutics for women’s health technologies market is expected to grow from $61.5 billion in 2024 and is projected to reach $81.2 billion by the end of 2029, at a compound annual growth rate (CAGR) of 5.7% during the forecast period of 2024 to 2029.

In 2023, the global therapeutics for women’s health technologies market was valued at $58.3 billion. The market is forecast to grow at a CAGR of 5.7% to reach $81.2 billion by the end of 2029. The factors driving market growth are the growing population of older women and the rising awareness of and accessibility to healthcare and advanced therapeutic products. High treatment costs and regulatory challenges are restraining the market’s growth. In 2023, the breast cancer segment of the global therapeutics for women’s health technologies held the largest share, 55.1% of the market segmented by women’s health disorders, and this segment is expected to grow at a CAGR of 5.9% during the forecast period.

Report Scope

This report provides a detailed analysis of the global therapeutics for women’s health technologies market, including coverage of market drivers, restraints and opportunities. It also includes analyses of this market’s competitive environment and products. The report presents market estimates and forecasts for women’s health therapeutics and provides market projections through 2029. For this analysis, the market is segmented by conditions related to women’s health, including breast cancer, postmenopausal osteoporosis, menopause, endometriosis and polycystic ovary syndrome (PCOS), and by geographic region. The report provides company profiles of the market’s leading players that feature detailed information about each company’s business segments, financials, product portfolios and recent developments.

By region, the global therapeutics for women’s health technologies market is segmented into North America, Europe, Asia-Pacific and the Rest of the World (RoW). The North American region includes the U.S., Canada and Mexico. Europe includes the U.K., Germany, Spain, France, Italy and the Rest of Europe; Asia-Pacific comprises China, Japan, India, Australia, South Korea and the Rest of Asia-Pacific. The rest of the World includes the Middle East and Africa, and South America. In the report’s market estimates, 2021 and 2022 serve as historical years, 2023 as the base year, and data forecasts are given through 2029.

The report includes:

  • 46 data tables and 63 additional tables
  • An overview of the global market and technologies for women's health therapeutics
  • Analyses of the global market trends, with sales data for 2021-2023, estimates for 2024, and projections of compound annual growth rates (CAGRs) through 2029
  • Study of women’s diseases such as endometriosis, postmenopausal osteoporosis, menopause, breast cancer and polycystic ovary syndrome (PCOS), including their historical background, stages, symptoms, risk factors and genetic factors, diagnosis, and treatment options
  • Discussion on aging and women’s health disorders, women and sexual health such as female sexual arousal disorder, female orgasmic disorder and vaginismus, as well as the relationship between infertility and cancer
  • Information about significant products, companies, issues and trends affecting the women’s disorders and diseases industry
  • Evaluation of the impact of demographic, economic and other factors that will drive demand in the market for women’s health therapeutics
  • Coverage of regulatory structure, pricing, and reimbursement scenarios; marketed and pipeline (R&D) products, and clinical trials
  • Identification of the market drivers, restraints and other forces impacting the global market, as well as an evaluation of current and projected market size
  • A discussion of ESG challenges and practices in the industry
  • Market share analysis of the key companies and coverage of their proprietary technologies, strategic alliances, and other market strategies
  • Profiles of the leading companies, including F. Hoffmann-La Roche Ltd., Pfizer Inc., Eli Lilly and Company, Novartis AG and Amgen Inc.

Table of Contents

Chapter 1 Executive Summary
  • Market Outlook
  • Scope of Report
  • Market Insights
Chapter 2 Market Overview
  • Overview
  • Definitions
  • Breast Cancer
  • Postmenopausal Osteoporosis
  • Menopause
  • Endometriosis
  • Polycystic Ovary Syndrome (PCOS)
  • Historical Context
  • Aging and Women’s Health Disorders
Chapter 3 Market Dynamics
  • Overview
  • Market Drivers
  • Rising Population of Older Women
  • Increasing Awareness and Accessibility
  • Market Restraints
  • High Treatment Costs
  • Regulatory Challenges
  • Market Opportunities
  • Advances in Personalized Medicine
  • Emerging Markets
Chapter 4 Emerging Technologies
  • Overview
  • Digital Health Solutions
  • Advanced Fertility Technologies
  • Targeted Biologics and Biosimilars
  • Nanotechnology-Driven Drug Delivery
  • Gene Therapy and CRISPR
Chapter 5 Pipeline Assessment and Analysis
  • Overview
  • Women’s Health Therapeutics: Key Clinical Trial Developments
  • Drugs in Pipeline
  • Overview of Osteoporosis Drug Development Pipeline
Chapter 6 Regulatory Structure
  • Overview of Regulations
  • U.S.
  • Drug Development and Approval Process
  • Types of Applications Reviewed by FDA
  • Canada
  • Food and Drugs Act (F-27)
  • Europe
  • Japan
Chapter 7 Market Segmentation Analysis
  • Segmentation Breakdown
  • Market Analysis, by Women’s Health Disorder
  • Breast Cancer
  • Postmenopausal Osteoporosis
  • Menopause
  • Endometriosis
  • PCOS
  • Geographic Breakdown
  • Market Analysis, by Region
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
Chapter 8 Competitive Landscape
  • Overview
  • Market Players and Strategies
  • Patent Analysis
  • Key Developments
Chapter 9 ESG Perspective
  • Introduction to ESG
  • ESG Goals for the Pharmaceutical Sector
  • Focus on Energy Efficiency
  • Reduce Emissions and Carbon Footprint
  • Waste Generation and Disposal
  • Manufacturing, Distribution and Transportation
  • Social Responsibility
  • Governance
  • ESG Risk Ratings in the Pharmaceutical Industry
  • Concluding Remarks
Chapter 10 Appendix
  • Methodology
  • Sources
  • Abbreviations
  • Company Profiles
  • ABBVIE INC.
  • AMGEN INC.
  • ASAHI KASEI CORP.
  • ASTRAZENECA
  • BAYER AG
  • BRISTOL-MYERS SQUIBB CO.
  • EISAI CO. LTD.
  • F. HOFFMANN-LA ROCHE LTD.
  • JOHNSON & JOHNSON SERVICES INC.
  • LILLY
  • MERCK & CO. INC.
  • NOVARTIS AG
  • NOVO NORDISK A/S
  • PFIZER INC.
  • TEVA PHARMACEUTICAL INDUSTRIES LTD.
List of Tables
Summary Table: Global Therapeutics for Women’s Health Technologies Market, by Region, Through 2029
Table 1: Significant Events in Women's Health History in the U.S., 1983-Post-2000
Table 2: Key Clinical Trial Developments, 2024
Table 3: Novel Breast Cancer Drug Approvals, 2020
Table 4: Pipeline Drugs for Treating Endometriosis
Table 5: Pipeline Drugs for Treating Uterine Fibroids
Table 6: Pipeline Drugs for Treating Osteoporosis
Table 7: Key European Regulations and Directives Impacting Women's Health
Table 8: Global Therapeutics for Women’s Health Technologies Market, by Women’s Health Disorder, Through 2029
Table 9: Factors That Increase the Relative Risk for Invasive Breast Cancer in Women
Table 10: TNM Classification of Breast Cancers
Table 11: Drugs Commonly Used to Treat Breast Cancer
Table 12: Global Breast Cancer Market in Therapeutics for Women’s Health, by Region, Through 2029
Table 13: Global Postmenopausal Osteoporosis Market in Therapeutics for Women’s Health, by Region, Through 2029
Table 14: FDA-Approved Estrogen-Only Medicines
Table 15: FDA-Approved Progestin-Only Medicines
Table 16: FDA Approved Combination, Estrogen and Progestin Medicines
Table 17: FDA-Approved Combination Estrogen and Hormone Medicines
Table 18: Global Menopause Market in Therapeutics for Women’s Health, by Region, Through 2029
Table 19: Global Endometriosis Market in Therapeutics for Women’s Health, by Region, Through 2029
Table 20: Commonly Prescribed Generic Drugs for the Treatment of PCOS
Table 21: Global PCOS Market in Therapeutics for Women’s Health, by Region, Through 2029
Table 22: Global Therapeutics for Women’s Health Technologies Market, by Region, Through 2029
Table 23: North American Therapeutics for Women’s Health Technologies Market, by Country, Through 2029
Table 24: North American Therapeutics for Women’s Health Technologies Market, by Women’s Health Disorder, Through 2029
Table 25: U.S. Therapeutics for Women’s Health Technologies Market, by Women’s Health Disorder, Through 2029
Table 26: Canadian Therapeutics for Women’s Health Technologies Market, by Women’s Health Disorder, Through 2029
Table 27: Mexican Therapeutics for Women’s Health Technologies Market, by Women’s Health Disorder, Through 2029
Table 28: European Therapeutics for Women’s Health Technologies Market, by Country, Through 2029
Table 29: European Therapeutics for Women’s Health Technologies Market, by Women’s Health Disorder, Through 2029
Table 30: German Therapeutics for Women’s Health Technologies Market, by Women’s Health Disorder, Through 2029
Table 31: U.K. Therapeutics for Women’s Health Technologies Market, by Women’s Health Disorder, Through 2029
Table 32: French Therapeutics for Women’s Health Technologies Market, by Women’s Health Disorder, Through 2029
Table 33: Italian Therapeutics for Women’s Health Technologies Market, by Women’s Health Disorder, Through 2029
Table 34: Spanish Therapeutics for Women’s Health Technologies Market, by Women’s Health Disorder, Through 2029
Table 35: Rest of European Therapeutics for Women’s Health Technologies Market, by Women’s Health Disorder, Through 2029
Table 36: Asia-Pacific Therapeutics for Women’s Health Technologies Market, by Country, Through 2029
Table 37: Asia-Pacific Therapeutics for Women’s Health Technologies Market, by Women’s Health Disorder, Through 2029
Table 38: Chinese Therapeutics for Women’s Health Technologies Market, by Women’s Health Disorder, Through 2029
Table 39: Japanese Therapeutics for Women’s Health Technologies Market, by Women’s Health Disorder, Through 2029
Table 40: Indian Therapeutics for Women’s Health Technologies Market, by Women’s Health Disorder, Through 2029
Table 41: Australian Therapeutics for Women’s Health Technologies Market, by Women’s Health Disorder, Through 2029
Table 42: South Korean Therapeutics for Women’s Health Technologies Market, by Women’s Health Disorder, Through 2029
Table 43: Rest of APAC Therapeutics for Women’s Health Technologies Market, by Women’s Health Disorder, Through 2029
Table 44: Rest of the World Therapeutics for Women’s Health Technologies Market, by Women’s Health Disorder, Through 2029
Table 45: Leading Companies in Therapeutics for Women’s Health Technologies, 2023
Table 46: Major Women’s Health Therapeutics Pharmaceuticals, 2023
Table 47: Active Patents of Key Competitor Companies, 2024
Table 48: Approvals for Novel Drugs for Therapeutics for Women’s Health Technologies, 2021
Table 49: Selected New Women’s Health Therapeutic Drugs in Late Stages of Clinical Development
Table 50: ESG Rankings for Leading Players in Therapeutics for Women’s Health Technologies Market, 2024
Table 51: Information Sources in This Report
Table 52: Glossary of Terms Used in the DNA Sequencing Market
Table 53: AbbVie Inc.: Company Snapshot
Table 54: AbbVie Inc.: Financial Performance, FY 2022 and 2023
Table 55: AbbVie Inc.: Product Portfolio
Table 56: AbbVie Inc.: News/Key Developments, 2022
Table 57: Amgen Inc.: Company Snapshot
Table 58: Amgen Inc.: Financial Performance, FY 2022 and 2023
Table 59: Amgen Inc.: Product Portfolio
Table 60: Amgen Inc.: News/Key Developments, 2023
Table 61: Asahi Kasei Corp.: Company Snapshot
Table 62: Asahi Kasei Corp.: Financial Performance, FY 2022 and 2023
Table 63: Asahi Kasei Corp.: Product Portfolio
Table 64: AstraZeneca: Company Snapshot
Table 65: AstraZeneca: Financial Performance, FY 2022 and 2023
Table 66: AstraZeneca: Product Portfolio
Table 67: AstraZeneca: News/Key Developments, 2023 and 2024
Table 68: Bayer AG: Company Snapshot
Table 69: Bayer AG: Financial Performance, FY 2022 and 2023
Table 70: Bayer AG: Product Portfolio
Table 71: Bayer AG: News/Key Developments, 2024
Table 72: Bristol-Myers Squibb Co.: Company Snapshot
Table 73: Bristol-Myers Squibb Co.: Financial Performance, FY 2022 and 2023
Table 74: Bristol-Myers Squibb Co.: Product Portfolio
Table 75: Eisai Co. Ltd.: Company Snapshot
Table 76: Eisai Co. Ltd.: Financial Performance, FY 2022 and 2023
Table 77: Eisai Co. Ltd.: Product Portfolio
Table 78: F. Hoffmann-La Roche Ltd.: Company Snapshot
Table 79: F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2022 and 2023
Table 80: F. Hoffmann-La Roche Ltd.: Product Portfolio
Table 81: F. Hoffmann-La Roche Ltd.: News/Key Developments, 2023 and 2024
Table 82: Johnson & Johnson Services Inc.: Company Snapshot
Table 83: Johnson & Johnson Services Inc.: Financial Performance, FY 2022 and 2023
Table 84: Johnson & Johnson Services Inc.: Product Portfolio
Table 85: Lilly: Company Snapshot
Table 86: Lilly: Financial Performance, FY 2022 and 2023
Table 87: Lilly: Product Portfolio
Table 88: Lilly: News/Key Developments, 2023
Table 89: Merck & Co. Inc.: Company Snapshot
Table 90: Merck & Co. Inc.: Financial Performance, FY 2022 and 2023
Table 91: Merck & Co. Inc.: Product Portfolio
Table 92: Merck & Co. Inc.: News/Key Developments, 2024
Table 93: Novartis AG: Company Snapshot
Table 94: Novartis AG: Financial Performance, FY 2022 and 2023
Table 95: Novartis AG: Product Portfolio
Table 96: Novartis AG: News/Key Developments, 2022 and 2024
Table 97: Novo Nordisk A/S: Company Snapshot
Table 98: Novo Nordisk A/S: Financial Performance, FY 2022 and 2023
Table 99: Novo Nordisk A/S: Product Portfolio
Table 100: Novo Nordisk A/S: News/Key Developments, 2022 and 2024
Table 101: Pfizer Inc.: Company Snapshot
Table 102: Pfizer Inc.: Financial Performance, FY 2022 and 2023
Table 103: Pfizer Inc.: Product Portfolio
Table 104: Pfizer Inc.: News/Key Developments, 2022
Table 105: Teva Pharmaceutical Industries Ltd.: Company Snapshot
Table 106: Teva Pharmaceutical Industries Ltd.: Financial Performance, FY 2022 and 2023
Table 107: Teva Pharmaceutical Industries Ltd.: Product Portfolio
Table 108: Teva Pharmaceutical Industries Ltd.: News/Key Developments, 2023 and 2024
List of Figures
Summary Figure: Global Therapeutics for Women’s Health Technologies Market Shares, by Region, 2023
Figure 1: Snapshot of Market Dynamics
Figure 2: Global Therapeutics for Women’s Health Technologies Market Shares, by Women’s Health Disorder, 2023
Figure 3: Global Breast Cancer Market in Therapeutics for Women’s Health Technologies, 2021-2029
Figure 4: Global Breast Cancer Market in Therapeutics for Women’s Health, by Region, 2021-2029
Figure 5: Global Postmenopausal Osteoporosis Market in Therapeutics for Women’s Health, 2021-2029
Figure 6: Global Postmenopausal Osteoporosis Market in Therapeutics for Women’s Health, by Region, 2021-2029
Figure 7: Global Menopause Market in Therapeutics for Women’s Health, 2021-2029
Figure 8: Global Menopause Market in Therapeutics for Women’s Health, by Region, 2021-2029
Figure 9: Global Endometriosis Market in Therapeutics for Women’s Health, 2021-2029
Figure 10: Global Endometriosis Market in Therapeutics for Women’s Health, by Region, 2021-2029
Figure 11: Global PCOS Market in Therapeutics for Women’s Health, 2021-2029
Figure 12: Global PCOS Market in Therapeutics for Women’s Health, by Region, 2021-2029
Figure 13: Global Therapeutics for Women’s Health Technologies Market Shares, by Region, 2023
Figure 14: Global Therapeutics for Women’s Health Technologies Market, by Region, 2021-2029
Figure 15: North American Therapeutics for Women’s Health Technologies Market Shares, by Country, 2023
Figure 16: U.S. Therapeutics for Women’s Health Technologies Market, 2021-2029
Figure 17: Canadian Therapeutics for Women’s Health Technologies Market, 2021-2029
Figure 18: Mexican Therapeutics for Women’s Health Technologies Market, 2021-2029
Figure 19: European Therapeutics for Women’s Health Technologies Market Shares, by Country, 2023
Figure 20: German Therapeutics for Women’s Health Technologies Market, 2021-2029
Figure 21: U.K. Therapeutics for Women’s Health Technologies Market, 2021-2029
Figure 22: French Therapeutics for Women’s Health Technologies Market, 2021-2029
Figure 23: Italian Therapeutics for Women’s Health Technologies Market, 2021-2029
Figure 24: Spanish Therapeutics for Women’s Health Technologies Market, 2021-2029
Figure 25: Rest of European Therapeutics for Women’s Health Technologies Market, 2021-2029
Figure 26: Asia-Pacific Therapeutics for Women’s Health Technologies Market Shares, by Country, 2023
Figure 27: Chinese Therapeutics for Women’s Health Technologies Market, 2021-2029
Figure 28: Japanese Therapeutics for Women’s Health Technologies Market, 2021-2029
Figure 29: Indian Therapeutics for Women’s Health Technologies Market, 2021-2029
Figure 30: Australian Therapeutics for Women’s Health Technologies Market, 2021-2029
Figure 31: South Korean Therapeutics for Women’s Health Technologies Market, 2021-2029
Figure 32: Rest of APAC Therapeutics for Women’s Health Technologies Market, 2021-2029
Figure 33: Rest of the World Therapeutics for Women’s Health Technologies Market, 2021-2029
Figure 34: Snapshot of ESG Pillars
Figure 35: Advantages of ESG for Companies
Figure 36: AbbVie Inc.: Revenue Shares, by Business Unit, FY 2023
Figure 37: AbbVie Inc.: Revenue Shares, by Country/Region, FY 2023
Figure 38: Amgen Inc.: Revenue Shares, by Business Unit, FY 2023
Figure 39: Amgen Inc.: Revenue Shares, by Country/Region, FY 2023
Figure 40: Asahi Kasei Corp.: Revenue Shares, by Business Unit, FY 2023
Figure 41: Asahi Kasei Corp.: Revenue Shares, by Country/Region, FY 2023
Figure 42: AstraZeneca: Revenue Shares, by Business Unit, FY 2023
Figure 43: AstraZeneca: Revenue Shares, by Country/Region, FY 2023
Figure 44: Bayer AG: Revenue Shares, by Business Unit, FY 2023
Figure 45: Bayer AG: Revenue Shares, by Country/Region, FY 2023
Figure 46: Bristol-Myers Squibb Co.: Revenue Shares, by Business Unit, FY 2023
Figure 47: Bristol-Myers Squibb Co.: Revenue Shares, by Country/Region, FY 2023
Figure 48: Eisai Co. Ltd.: Revenue Shares, by Business Unit, FY 2023
Figure 49: Eisai Co. Ltd.: Revenue Shares, by Country/Region, FY 2023
Figure 50: F. Hoffmann-La Roche Ltd.: Revenue Shares, by Business Unit, FY 2023
Figure 51: F. Hoffmann-La Roche Ltd.: Revenue Shares, by Country/Region, FY 2023
Figure 52: Johnson & Johnson Services Inc.: Revenue Shares, by Business Unit, FY 2023
Figure 53: Johnson & Johnson Services Inc.: Revenue Shares, by Country/Region, FY 2023
Figure 54: Lilly: Revenue Shares, by Business Unit, FY 2023
Figure 55: Lilly: Revenue Shares, by Country/Region, FY 2023
Figure 56: Merck & Co. Inc.: Revenue Shares, by Business Unit, FY 2023
Figure 57: Merck & Co. Inc.: Revenue Shares, by Country/Region, FY 2023
Figure 58: Novartis AG: Revenue Shares, by Business Unit, FY 2023
Figure 59: Novartis AG: Revenue Shares, by Country/Region, FY 2023
Figure 60: Novo Nordisk A/S: Revenue Shares, by Business Unit, FY 2023
Figure 61: Novo Nordisk A/S: Revenue Shares, by Country/Region, FY 2023
Figure 62: Pfizer Inc.: Revenue Shares, by Business Unit, FY 2023
Figure 63: Pfizer Inc.: Revenue Shares, by Country/Region, FY 2023
Figure 64: Teva Pharmaceutical Industries Ltd.: Revenue Shares, by Country/Region, FY 2023

Companies Mentioned

  • AbbVie Inc.
  • Amgen Inc.
  • Asahi Kasei Corp.
  • AstraZeneca
  • Bayer AG
  • Bristol-Myers Squibb Co.
  • Eisai Co. Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Johnson & Johnson Services Inc.
  • Lilly
  • Merck & Co. Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.

Table Information

Report AttributeDetails
No. of Pages159
PublishedMarch 2025
Forecast Period2024 - 2029
Estimated Market Value ( USD ) in 2024 $ 61.5 Billion
Forecasted Market Value ( USD ) by 2029 $ 81.2 Billion
Compound Annual Growth Rate5.7%
Regions CoveredGlobal
No. of Companies Mentioned15

Related Topics

Related Reports

Women's Health Therapeutics Market by Type, Distribution Channel - Global Forecast 2025-2030 - Product Image

Women's Health Therapeutics Market by Type, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 181 Pages
  • Global
From
Women's Health Therapeutics - Global Strategic Business Report - Product Image

Women's Health Therapeutics - Global Strategic Business Report

  • Report
  • 92 Pages
  • Global
From
Women's Health Market Report 2025 - Product Image

Women's Health Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Women's Health Market by Age, Distribution Channel, Application - Global Forecast 2025-2030 - Product Image

Women's Health Market by Age, Distribution Channel, Application - Global Forecast 2025-2030

  • Report
  • 194 Pages
  • Global
From
Women Health Therapeutics Market 2024-2028 - Product Image

Women Health Therapeutics Market 2024-2028

  • Report
  • 180 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.